Identification of Compounds With Glucocorticoid Sparing Effects on Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
chemokine
chemotype
cytokine
fibroblast
glucocorticoid
high throughput screen
rheumatoid arthritis
synoviocyte
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
09
2020
accepted:
04
11
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
epublish
Résumé
In recent years target based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances and adverse effects, glucocorticoids remain reliable agents that are used in many of these diseases. The anti-inflammatory mechanisms of glucocorticoids include the suppression of transcription factor activity like nuclear factor kappa B (NF-κB). By reanalyzing data from two prior high throughput screens (HTS) that utilized a NF-κB reporter construct in THP-1 cells, we identified 1824 small molecule synthetic compounds that demonstrated NF-κB suppressive activities similar to the glucocorticoids included in the original >134,000 compound libraries. These 1824 compounds were then rescreened for attenuating NF-κB activity at 5 and 16 h after LPS stimuli in the NF-κB THP-1 reporter cells. After a "Top X" selection approach 122 hit compounds were further tested for toxicity and suppression of LPS induced CXCL8 release in THP-1 cells. Excluding cytotoxic compounds, the remaining active compounds were grouped into chemotype families using Tanimoto based clustering. Promising representatives from clustered chemotype groups were commercially purchased for further testing. Amongst these index compounds a lead chemotype: 1
Identifiants
pubmed: 33390996
doi: 10.3389/fphar.2020.607713
pii: 607713
pmc: PMC7773657
doi:
Types de publication
Journal Article
Langues
eng
Pagination
607713Informations de copyright
Copyright © 2020 Hosoya, Shukla, Fujita, Yao, Lao, Baba, Yasuda, Cottam, Carson, Hayashi and Corr.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arthritis Rheumatol. 2015 Oct;67(10):2581-90
pubmed: 26138901
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5626-30
pubmed: 18793851
Rheumatology (Oxford). 2015 Jan;54(1):178-87
pubmed: 25118313
Sci Adv. 2020 Jun 26;6(26):eaba4353
pubmed: 32637608
Oncotarget. 2015 Oct 13;6(31):30730-44
pubmed: 26436695
Ann Rheum Dis. 2015 Oct;74(10):1799-807
pubmed: 26359488
Nat Rev Rheumatol. 2020 Mar;16(3):133-144
pubmed: 32034322
Nature. 2000 Jan 6;403(6765):103-8
pubmed: 10638762
Cardiovasc Res. 2006 Feb 15;69(3):614-24
pubmed: 16266693
Medicine (Baltimore). 2015 Apr;94(15):e647
pubmed: 25881838
Cell. 2007 Sep 7;130(5):918-31
pubmed: 17803913
Inflamm Res. 2002 Apr;51(4):188-94
pubmed: 12058956
Ann Rheum Dis. 2013 Aug;72(8):1280-6
pubmed: 23740227
Lupus Sci Med. 2017 Feb 2;4(1):e000182
pubmed: 28243455
RMD Open. 2020 Jan;6(1):
pubmed: 31958273
Biochim Biophys Acta. 2010 Jan;1803(1):3-19
pubmed: 19631700
J Immunol. 2009 Jun 1;182(11):7201-11
pubmed: 19454717
N Engl J Med. 2013 Dec 26;369(26):2504-14
pubmed: 24369075
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):227-32
pubmed: 14694204
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Cell. 2017 Jan 12;168(1-2):37-57
pubmed: 28086098
Nat Genet. 2001 Mar;27(3):277-85
pubmed: 11242109
Arthritis Rheumatol. 2015 Sep;67(9):2283-91
pubmed: 26138641
J Pharmacopuncture. 2019 Dec;22(4):210-224
pubmed: 31970018
Nat Genet. 2016 Jan;48(1):67-73
pubmed: 26642243
Blood. 2007 Jan 15;109(2):703-10
pubmed: 16973958
Ann Rheum Dis. 2016 Jan;75(1):253-9
pubmed: 25165034
Stat Med. 2012 Dec 30;31(30):4175-89
pubmed: 22763983
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Immunity. 2017 Feb 21;46(2):183-196
pubmed: 28228278
Oncogene. 2006 Oct 30;25(51):6887-99
pubmed: 17072334
Arthritis Rheum. 2006 Jul;54(7):2074-83
pubmed: 16802342
Expert Opin Pharmacother. 2016;17(2):181-92
pubmed: 26684262
Nat Rev Drug Discov. 2004 Jan;3(1):17-26
pubmed: 14708018
J Med Chem. 2013 Jun 13;56(11):4206-23
pubmed: 23656327
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Neuropharmacology. 2016 Mar;102:59-71
pubmed: 26522434
Ann Rheum Dis. 2013 Dec;72(12):1905-13
pubmed: 23873876
J Med Chem. 2017 Feb 9;60(3):839-885
pubmed: 27996267
Ann Rheum Dis. 2020 Jan;79(1):19-30
pubmed: 31270110
Cell. 2016 Aug 25;166(5):1215-1230.e20
pubmed: 27523608
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
ACS Comb Sci. 2017 Aug 14;19(8):533-543
pubmed: 28657707
Front Endocrinol (Lausanne). 2016 Apr 19;7:31
pubmed: 27148162
Front Med (Lausanne). 2019 Jun 26;6:144
pubmed: 31294026
J Neuroimmune Pharmacol. 2016 Jun;11(2):231-7
pubmed: 26872456
Arthritis Res Ther. 2008;10(4):212
pubmed: 18771589
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945